A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
Status:
Completed
Trial end date:
2017-09-07
Target enrollment:
Participant gender:
Summary
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with
Microsatellite Stable Refractory Metastatic Colorectal Cancer